Decreased Epstein-Barr virus-induced transformation, and elevated 2-5A synthetase and RNase L activity in peripheral blood mononuclear cells from patients treated with recombinant interferon alfa 2b.
Patients with cutaneous T-cell lymphoma (CTCL) were treated with recombinant alfa 2b interferon (rIFN alfa 2b) by intramuscular injection. Therapy-induced changes in Epstein-Barr virus (EBV) induced transformation of patient peripheral blood lymphocytes, 2',5' oligoadenylate (2-5A) synthetase levels and RNase L activation in peripheral blood mononuclear cells were monitored. Inhibition of EBV-induced transformation and elevation of 2-5A synthetase levels correlated with increased activation of RNase L, which provides evidence that intramuscular administration of rIFN alfa 2b induces a sustained anti-EBV state in CTCL patient peripheral blood mononuclear cells which can be detected in vitro.
Fronko
G E
GE
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140.
Suhadolnik
R J
RJ
Vonderheid
E C
EC
Karikó
K
K
Reichenbach
N L
NL
Chavin
K D
KD
Henderson
E E
EE
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000328:Adult; D000818:Animals; D002472:Cell Transformation, Viral; D002986:Clinical Trials as Topic; D004722:Endoribonucleases / Q000097:blood*; D004854:Herpesvirus 4, Human; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000201:enzymology*; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013601:T-Lymphocytes
D007370:Interferon Type I; D011994:Recombinant Proteins; D015088:2',5'-Oligoadenylate Synthetase; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease